Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Respiratory Hypersensitivity

ClinicalTrials.gov lists 5,587 trials for Respiratory Hypersensitivity or a narrower condition beneath it. AstraZeneca has the most among industry and government lead sponsors, with 336.

MeSH D012130 Respiratory Tract Diseases C08 C20
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 458 Phase 1/2 Phase 1/2 73 Phase 2 Phase 2 746 Phase 2/3 Phase 2/3 71 Phase 3 Phase 3 820 Phase 4 Phase 4 594 Not applicable Not applicable 1,402 Observational Observational 1,421 Phase 1 Phase 1 458 Phase 1/2 Phase 1/2 73 Phase 2 Phase 2 746 Phase 2/3 Phase 2/3 71 Phase 3 Phase 3 820 Phase 4 Phase 4 594 Not applicable Not applicable 1,402 Observational Observational 1,421

Trials per phase (log scale)

1 more section with rows

44 of the 5,587 trials are tagged with Respiratory Hypersensitivity itself; the rest are tagged with a narrower condition beneath it.

Get the Respiratory Hypersensitivity report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Respiratory Hypersensitivity trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 7 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 282

1990: 9 trials (Observational 7, Not applicable 1, Phase 3 1) 1991: 5 trials (Observational 4, Phase 3 1) 1992: 7 trials (Observational 5, Not applicable 1, Phase 4 1) 1993: 6 trials (Observational 3, Phase 4 1, Phase 3 2) 1994: 8 trials (Observational 4, Not applicable 1, Phase 3 3) 1995: 7 trials (Observational 5, Phase 3 2) 1996: 12 trials (Observational 5, Not applicable 3, Phase 4 1, Phase 3 2, Phase 2 1) 1997: 11 trials (Observational 5, Not applicable 1, Phase 4 1, Phase 3 3, Phase 2 1) 1998: 18 trials (Observational 5, Not applicable 3, Phase 4 4, Phase 3 5, Phase 2 1) 1999: 32 trials (Observational 16, Not applicable 5, Phase 4 2, Phase 3 5, Phase 2/3 1, Phase 2 3) 2000: 35 trials (Observational 14, Not applicable 5, Phase 4 5, Phase 3 9, Phase 2/3 1, Phase 1/2 1) 2001: 45 trials (Observational 11, Not applicable 13, Phase 4 4, Phase 3 11, Phase 2 5, Phase 1 1) 2002: 85 trials (Observational 8, Not applicable 12, Phase 4 23, Phase 3 28, Phase 2 12, Phase 1/2 1, Phase 1 1) 2003: 112 trials (Observational 10, Not applicable 25, Phase 4 30, Phase 3 38, Phase 2 9) 2004: 137 trials (Observational 22, Not applicable 24, Phase 4 24, Phase 3 44, Phase 2/3 4, Phase 2 15, Phase 1 4) 2005: 185 trials (Observational 33, Not applicable 28, Phase 4 30, Phase 3 55, Phase 2/3 4, Phase 2 21, Phase 1/2 2, Phase 1 12) 2006: 219 trials (Observational 30, Not applicable 39, Phase 4 44, Phase 3 44, Phase 2/3 7, Phase 2 33, Phase 1/2 7, Phase 1 15) 2007: 269 trials (Observational 65, Not applicable 39, Phase 4 53, Phase 3 42, Phase 2/3 1, Phase 2 43, Phase 1/2 2, Phase 1 24) 2008: 262 trials (Observational 53, Not applicable 48, Phase 4 30, Phase 3 33, Phase 2/3 1, Phase 2 61, Phase 1/2 6, Phase 1 30) 2009: 260 trials (Observational 64, Not applicable 53, Phase 4 32, Phase 3 25, Phase 2/3 5, Phase 2 52, Phase 1/2 5, Phase 1 24) 2010: 271 trials (Observational 52, Not applicable 42, Phase 4 24, Phase 3 37, Phase 2/3 8, Phase 2 66, Phase 1/2 6, Phase 1 36) 2011: 257 trials (Observational 64, Not applicable 54, Phase 4 24, Phase 3 46, Phase 2/3 3, Phase 2 37, Phase 1/2 3, Phase 1 26) 2012: 282 trials (Observational 57, Not applicable 73, Phase 4 17, Phase 3 37, Phase 2/3 3, Phase 2 63, Phase 1/2 6, Phase 1 26) 2013: 209 trials (Observational 38, Not applicable 44, Phase 4 23, Phase 3 32, Phase 2/3 5, Phase 2 38, Phase 1/2 3, Phase 1 26) 2014: 200 trials (Observational 31, Not applicable 57, Phase 4 21, Phase 3 36, Phase 2/3 3, Phase 2 27, Phase 1/2 2, Phase 1 23) 2015: 238 trials (Observational 58, Not applicable 71, Phase 4 20, Phase 3 33, Phase 2/3 5, Phase 2 32, Phase 1/2 3, Phase 1 16) 2016: 223 trials (Observational 50, Not applicable 71, Phase 4 21, Phase 3 29, Phase 2/3 3, Phase 2 20, Phase 1/2 2, Phase 1 27) 2017: 226 trials (Observational 65, Not applicable 67, Phase 4 14, Phase 3 27, Phase 2/3 3, Phase 2 26, Phase 1/2 3, Phase 1 21) 2018: 201 trials (Observational 62, Not applicable 56, Phase 4 20, Phase 3 32, Phase 2 17, Phase 1/2 2, Phase 1 12) 2019: 219 trials (Observational 66, Not applicable 70, Phase 4 16, Phase 3 25, Phase 2/3 1, Phase 2 17, Phase 1/2 3, Phase 1 21) 2020: 174 trials (Observational 70, Not applicable 49, Phase 4 16, Phase 3 12, Phase 2/3 3, Phase 2 13, Phase 1/2 1, Phase 1 10) 2021: 237 trials (Observational 98, Not applicable 57, Phase 4 23, Phase 3 16, Phase 2/3 2, Phase 2 13, Phase 1/2 3, Phase 1 25) 2022: 225 trials (Observational 73, Not applicable 71, Phase 4 13, Phase 3 21, Phase 2/3 2, Phase 2 23, Phase 1/2 5, Phase 1 17) 2023: 224 trials (Observational 72, Not applicable 78, Phase 4 9, Phase 3 23, Phase 2/3 2, Phase 2 20, Phase 1/2 2, Phase 1 18) 2024: 248 trials (Observational 80, Not applicable 92, Phase 4 19, Phase 3 23, Phase 2/3 1, Phase 2 17, Phase 1/2 1, Phase 1 15) 2025: 205 trials (Observational 60, Not applicable 70, Phase 4 11, Phase 3 15, Phase 2/3 3, Phase 2 29, Phase 1/2 2, Phase 1 15)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 172
2025 205
2024 248
2023 224
2022 225
2021 237
2020 174
2019 219
2018 201
2017 226

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 200 trials starting in 2026 and about 210 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 33 months from start to primary completion across 251 trials still running at the 2026-10-09 snapshot; registered median of 16 months across 3,971 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Respiratory Hypersensitivity trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 458
Phase 1/2 73
Phase 2 746
Phase 2/3 71
Phase 3 820
Phase 4 594
Not applicable 1,402
Observational 1,421
Expanded access 2

How many Respiratory Hypersensitivity trials are recruiting? (11)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 142
Recruiting 350
Enrolling by invitation 27
Active, not recruiting 121
Completed 3,903

Showing 5 of 11 statuses.

Start your 14-day trial Email me all 11 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Respiratory Hypersensitivity trials? (11)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
AstraZeneca 336
GlaxoSmithKline 324
Organon and Co 127
Novartis Pharmaceuticals 81
National Heart, Lung, and Blood Institute (NHLBI) 76

Showing 5 of 11 sponsors.

Start your 14-day trial Email me all 11 sponsors as a PDF

Which drugs are being tested for Respiratory Hypersensitivity? (5)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Montelukast 131
OPN-375 125
Albuterol 56
Formoterol 32
LYR-210 31

Interventions as named in the registry (10)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Budesonide EC 79
Drug: Omalizumab 75
Fluticasone foroate 53
Ciclesonide HFA 49
Mepolizumab SC 47

Showing 5 of 10 interventions.

Start your 14-day trial Email me all 10 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Respiratory Hypersensitivity trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Invasive cancer of any type 4,851 1
Asthma 3,011 245
Major cardiovascular event 2,415 1
Gastrointestinal bleeding 2,232 1
Pneumonia 903 173

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Respiratory Hypersensitivity? (156)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
The effect of tezepelumab on airway hyperresponsiveness to mannitol in asthma (UPSTREAM). The European respiratory journal 2022 Yes
Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. The Lancet. Respiratory medicine 2021 Yes
Specific gut microbiome signatures and the associated pro-inflamatory functions are linked to pediatric allergy and acquisition of immune tolerance. Nature communications 2021 Yes
Risk Factors for Olfactory and Gustatory Dysfunctions in Patients with SARS-CoV-2 Infection. Neuroepidemiology 2021 Yes
Respiratory Duty Cycles in Individuals With and Without Airway Hyperresponsiveness. Chest 2020 Yes

Showing 5 of 156 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (5)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages